Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
10 hedge funds and large institutions have $19.8M invested in Anebulo Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
16% more capital invested
Capital invested by funds: $17.1M → $19.8M (+$2.76M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.82% less ownership
Funds ownership: 27.49% → 26.67% (-0.82%)
17% less funds holding
Funds holding: 12 → 10 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.29K |
| 2 |
BlackRock
New York
|
+$682 |
| 3 |
JP Morgan Chase
New York
|
+$45 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Praetorian Capital Management
Coral Gables,
Florida
|
-$436K |
| 2 |
HIG
Herr Investment Group
Austin,
Texas
|
-$71.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.1K |
| 4 |
LA
LVW Advisors
Pittsford,
New York
|
-$1.66K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $14.7M | – | – | – |
|
|
LA
2
LVW Advisors
Pittsford,
New York
| $1.95M | -$1.66K | -583 | -0.1% |
|
|
NCM
3
Nantahala Capital Management
New Canaan,
Connecticut
| $1.48M | – | – | – |
|
|
MP
4
Mangrove Partners
Greenwich,
Connecticut
| $1.16M | – | – | – |
|
|
IC
5
Ikarian Capital
Dallas,
Texas
| $462K | – | – | – |
|
|
BFM
6
Boothbay Fund Management
New York
| $50.2K | – | – | – |
|
|
7
BlackRock
New York
| $21.8K | +$682 | +240 | +3% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $15K | +$4.29K | +1,510 | +42% |
|
|
9
Wells Fargo
San Francisco,
California
| $160 | +$3 | +1 | +2% |
|
|
PCM
10
Praetorian Capital Management
Coral Gables,
Florida
| – | -$436K | -180,005 | Closed |
|
|
HIG
11
Herr Investment Group
Austin,
Texas
| – | -$71.8K | -29,644 | Closed |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$4.1K | -1,696 | Closed |
|
|
13
JP Morgan Chase
New York
| – | +$45 | +16 | New |
|
ANEB Hedge Fund Activity: Q1 2023 in Review
10 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q1 2023, worth a combined $19.8M — up 16% from $17.1M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ANEB and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $4.29K. The largest seller was Praetorian Capital Management, exiting entirely with an estimated $436K sold.
- 10 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q1 2023, down from 12 in Q4 2022.
- Funds reported $19.8M of Anebulo Pharmaceuticals stock for Q1 2023, up 16% quarter-over-quarter.
- 1 fund opened new Anebulo Pharmaceuticals positions in Q1 2023 and 3 closed out, a net change of -2 holders.
- The largest Anebulo Pharmaceuticals buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $4.29K added.
- The largest Anebulo Pharmaceuticals seller in Q1 2023 was Praetorian Capital Management, an estimated $436K sold.
Based on aggregated 13F filings for Q1 2023.